Skip to main content
. Author manuscript; available in PMC: 2022 Dec 21.
Published in final edited form as: Nat Med. 2020 Oct 12;26(12):1845–1851. doi: 10.1038/s41591-020-1086-y

Extended Data Fig. 2: Response rate in association with adverse events or variant histology.

Extended Data Fig. 2:

a. Pathologic response based on grade of immune-related adverse events.

b. Pathologic response in pure urothelial carcinoma vs. urothelial carcinoma with variant histology.